Seracini D, Pollini I, Lavoratti G C, Pela I, Materassi M, Danti D, De Simone L, Favilli S, Manetti A
Divisione di Nefrologia e Dialisi, Università di Firenze, Italia.
Pediatr Med Chir. 1994 Jul-Aug;16(4):389-92.
Recombinant human erythropoietin (r-HuEPO) is efficient in the treatment of anaemia in chronic renal failure on hemodialysis. We investigated the changes in cardiac function under r-HuEPO therapy using echocardiography. Seven patients with severe renal anaemia (Ht 19%) were treated with 50 U/kg r-HuEPO EV three times/week. Echocardiographic studies were performed in the anemic state and when hematocrit values were stable at levels (Ht 30%). Left ventricular function as showed by fractional shortening (D%) improved, the thickness of the interventricular septum and left ventricular hypertrophy were reduced. Our data indicate that the correction of renal anaemia by r-HuEPO can improve myocardial function in patients on maintenance hemodialysis.
重组人促红细胞生成素（r-HuEPO）在治疗接受血液透析的慢性肾衰竭患者贫血方面疗效显著。我们使用超声心动图研究了r-HuEPO治疗期间心脏功能的变化。7例重度肾性贫血患者（血细胞比容为19%）接受每周3次、每次50 U/kg的r-HuEPO静脉注射治疗。在贫血状态以及血细胞比容稳定在30%时进行了超声心动图检查。结果显示，左心室功能通过缩短分数（D%）得到改善，室间隔厚度和左心室肥厚减轻。我们的数据表明，r-HuEPO纠正肾性贫血可改善维持性血液透析患者的心肌功能。
